GT Biopharma, Inc.GTBPNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank57
3Y CAGR-16.4%
5Y CAGR+12.9%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-16.4%/yr
vs -0.3%/yr prior
5Y CAGR
+12.9%/yr
Recent deceleration
Acceleration
-16.0pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
1.8x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $12.42M | -13.5% |
| 2024 | $14.36M | +5.8% |
| 2023 | $13.58M | -36.1% |
| 2022 | $21.26M | -63.0% |
| 2021 | $57.52M | +750.3% |
| 2020 | $6.76M | -40.9% |
| 2019 | $11.45M | -46.9% |
| 2018 | $21.55M | -84.1% |
| 2017 | $135.57M | +1346.2% |
| 2016 | $9.37M | - |